All
Q&A: Study Highlights KT-474's Effectiveness in Targeting IRAK4 for Hidradenitis Suppurativa and Other Inflammatory Diseases
Jared Gollob, MD, shares highlights of Kymera Therapeutics' recent JID publication.
Insights Into Positive Decision for Galderma's RelabotulinumtoxinA in Europe
Sachin Shridharani, MD, FACS, discusses the READY-1 and READY-2 clinical trials and positive support for Relfydess.
Navigating a Long-Term Journey: From Topicals to Systemic Therapies in AD
Kristine Kucera, MPAS, PA-C, DHS, discusses her patient's challenging atopic dermatitis that was eventually cleared with upadacitinib.
Derm In The News: August 4-10
Keep up with the latest headlines in dermatology from the past week, including the FDA's approval of Lymphir for CTCL, L'Oreal buying stake in Galderma, and more.
The Weekly Roundup: August 5-9
In case you missed it, this week we had news about the FDA approval of denileukin diftitox for relapsed or refractory cutaneous T-cell lymphoma, the initiated phase 3 trial of ESK-001 for plaque psoriasis, secukinumab for HS clusters, and more.
Study Solidifies Link Between Environment and Psoriasis Risk
Researchers linked higher exposure to natural environments and green spaces with an increased risk of developing psoriasis.
Delving Into NP/PA Perspectives on Emerging Atopic Dermatitis Treatment Options
Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.
Comparing AI Models for Dermatological Diagnoses
Researchers emphasized the need for improved reliability and regulatory frameworks for AI tools before they are integrated into dermatological practice.
Study Identifies 3 Hidradenitis Suppurativa Clusters and Evaluates Secukinumab Efficacy
Secukinumab improved outcomes in all clusters, with more frequent dosing benefiting severe cases.
Navigating the Challenges of Melasma Treatment and Achieving Trial Equity in Melanin-Rich Skin
Melasma, challenging due to varied pigmentation in different skin types, requires personalized, tailored care.
Psoriasis Does Not Increase Risk of COPD, According to New Study
Increased COPD prevalence in patients with psoriasis likely reflects smoking correlation, according to researchers.
Diamond-Augmented Zinc Oxide Technology Demonstrates Efficacy in Wound Healing, Collagen Synthesis, and More
ND-ZnO technology also demonstrated substantial skin permeation and active ingredient delivery.
Vitiligo Care Personalized for Each Patient: Part 1
Rocco Serrao, MD, FAAD, reviewed a case study of a 20-year-old man with segmental vitiligo and the psychological impact of his vitiligo.
Piperacillin/Tazobactam Shows Potential in Severe HS Treatment
Follow-up results showed that 6 out of 9 patients achieved HiSCR at 3 months, with 5 maintaining this response at 6 months.
FDA Approves Denileukin Diftitox for Adults With Relapsed or Refractory Cutaneous T-Cell Lymphoma
The approval is supported by positive phase 3 data for Lymphir in this indication.
Back to School, Back in the Spotlight
Young patients are heading back to school, and common skin issues like acne, eczema, warts, and pigmentation can affect their confidence, Shanna Miranti, MPAS, PA-C, writes.
Women With Skin of Color are Underrepresented in Studies of Treatments for Vulvar Lichen Sclerosus
Topical corticosteroids are the gold standard treatment for VLS, yet women with skin of color are not represented in studies.
Extended Guselkumab Dosing Proven Effective for Psoriasis
Both 8-week and 16-week dosing intervals of guselkumab achieved similar clinical outcomes and patient-reported responses in the GUIDE trial.
Study Achieves International Consensus for Methotrexate Dosing in Patients With Atopic Dermatitis
Researchers said they hope this consensus guides prescribing decisions among clinicians and encourages development of a standard approach.
From OX40 Inhibition to Pediatric Pearls: Back-to-School Time for Physicians and Patients Alike
Our August issue covers common back-to-school skin conditions, psoriasis research, OX40 inhibition for atopic dermatitis, and pediatric dermatology meeting highlights.
Experts Form Consensus on AI's Role in Aesthetics
A group of international experts focused on the technology’s potential to standardize and enhance patient assessments.
Vitiligo Risk Alleles Vary Across Different Populations, According to Study
The findings highlight the need for diverse genetic studies to understand their broader impact on autoimmune diseases.
JAK Inhibition With Upadacitinib and Abrocitinib Shows Potential in Rosacea Treatment
Recent research evaluated 6 patients with rosacea treated with JAK1 inhibitors upadacitinib and abrocitinib.
Screening Questionnaire Developed for Type 2 Inflammation Diseases
The 15-piece questionnaire is designed to be quick and easy to use during consultations, with particular benefits across numerous specialties.
Q&A: Alumis Inc. Initiates Phase 3 Clinical Program for ESK-001 in Plaque Psoriasis
Alumis' Martin Babler shared insights into the program for the TYK2 inhibitor and the company's next steps for its development.
Breakthrough CRISPR/Cas9 Technique Achieves 95% Exon Deletion for Epidermolysis Bullosa Treatment
A new method using 2 single-guide RNA/Cas9 tools to target 3 specific COL7A1 gene segments with harmful mutations successfully removed up to 95% of those segments.
Microneedling and CO2 Lasers Enhance Acne Treatment
A recent study revealed that CO2 fractional laser was significantly more effective than microneedling for acne treatment with ALA-PDT.
Relationship Between Vitiligo and Psoriasis May Be Due, In Part, to Immunity
Skin with vitiligo and psoriasis shows increased immune cell type, with a Mendelian analysis finding no causal link between the conditions.
Hand Dermatitis Relief: Cotton Gloves vs Sympatex Liners
Participants experienced improvements with both glove types, though cotton gloves were generally preferred for comfort and Sympatex for tactile sensitivity.
Journal Digest: August 5
This week’s collection of the latest dermatologic studies includes oral dutasteride for frontal fibrosing alopecia, effects of air pollutants for patients with acne, bimekizumab in patients with PsA without methotrexate, and itepekimab for adults with moderate to severe AD.
